pioglitazone has been researched along with Reperfusion Injury in 39 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Reperfusion Injury: Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Luteolin exerts neuroprotective roles against inflammation and autophagy of hippocampus induced by cerebral I/R by activating PPARγ in rats." | 8.12 | Luteolin alleviates inflammation and autophagy of hippocampus induced by cerebral ischemia/reperfusion by activating PPAR gamma in rats. ( Fan, R; Guo, L; Li, D; Li, L; Liang, H; Ma, L; Pan, G; Qiu, J, 2022) |
| "The present study investigated the role of N-methyl-D-aspartate (NMDA) receptors in pioglitazone-mediated protection against renal ischemia reperfusion injury (IRI) in rats." | 7.83 | Pioglitazone ameliorates renal ischemia reperfusion injury through NMDA receptor antagonism in rats. ( Bedi, PM; Singh, AP; Singh, N, 2016) |
| "In our previous study, we showed that pioglitazone exerts protective effects on renal ischemia-reperfusion injury (IRI) in mice by abrogating renal cell apoptosis." | 7.79 | Pioglitazone protects against renal ischemia-reperfusion injury by enhancing antioxidant capacity. ( Hu, H; Huang, X; Shi, Z; Wang, G; Xi, X; Zou, C, 2013) |
| " We examined the effects of pioglitazone, a synthetic ligand of PPAR-gamma, against lung ischemia-reperfusion injury in rats." | 7.72 | Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on lung ischemia-reperfusion injury in rats. ( Ito, K; Kato, D; Kitamura, N; Naito, Y; Shimada, J; Takagi, T; Toda, S; Yoshikawa, T, 2004) |
| "In rats subjected to cerebral ischemia, post-ischemic treatment with either dose of pioglitazone alleviated particular motor deficits and sensory impairments on day 2 after MCAO." | 6.77 | Treatment of rats with pioglitazone in the reperfusion phase of focal cerebral ischemia: a preclinical stroke trial. ( Culman, J; Glatz, T; Gohlke, P; Herdegen, T; Nguyen-Ngoc, M; Zhao, Y, 2012) |
| "Pioglitazone (10mg/kg; po) was administered daily for 2 weeks prior to I/R." | 5.42 | Neuroprotective effects of pioglitazone against transient cerebral ischemic reperfusion injury in diabetic rats: Modulation of antioxidant, anti-inflammatory, and anti-apoptotic biomarkers. ( Ain-Shoka, AA; Attia, AS; El-Sahar, AE; Safar, MM; Zaki, HF, 2015) |
| "Pioglitazone pretreatment also suppressed NF-κB activation and altered GFAP overexpression." | 5.39 | Protective effect of pioglitazone on retinal ischemia/reperfusion injury in rats. ( Xiao, YQ; Ye, W; Zhang, XY; Zhang, Y, 2013) |
| "Pioglitazone is a novel class of oral antidiabetic agents currently used to treat type 2 diabetes mellitus." | 5.38 | Protective effects of pioglitazone on renal ischemia-reperfusion injury in mice. ( Hu, H; Huang, X; Shi, Z; Wang, G; Xi, X; Zou, C, 2012) |
| "Pioglitazone pretreatment also attenuated the oxidative stress and DNA fragmentation after cerebral IR injury." | 5.35 | Protective effects of pioglitazone against global cerebral ischemic-reperfusion injury in gerbils. ( Iyer, S; Kaundal, RK; Kumar, A; Sharma, SS, 2009) |
| "Luteolin exerts neuroprotective roles against inflammation and autophagy of hippocampus induced by cerebral I/R by activating PPARγ in rats." | 4.12 | Luteolin alleviates inflammation and autophagy of hippocampus induced by cerebral ischemia/reperfusion by activating PPAR gamma in rats. ( Fan, R; Guo, L; Li, D; Li, L; Liang, H; Ma, L; Pan, G; Qiu, J, 2022) |
| "Recent researches highlighted the protective potential of pioglitazone, a PPAR-γ agonist, in the progression of cerebral ischemia-reperfusion injury." | 3.88 | Pioglitazone Confers Neuroprotection Against Ischemia-Induced Pyroptosis due to its Inhibitory Effects on HMGB-1/RAGE and Rac1/ROS Pathway by Activating PPAR-ɤ. ( Guo, Q; Pan, Y; Wang, E; Wang, N; Xia, P; Ye, Z; Zhang, F, 2018) |
| "The present study investigated the role of N-methyl-D-aspartate (NMDA) receptors in pioglitazone-mediated protection against renal ischemia reperfusion injury (IRI) in rats." | 3.83 | Pioglitazone ameliorates renal ischemia reperfusion injury through NMDA receptor antagonism in rats. ( Bedi, PM; Singh, AP; Singh, N, 2016) |
| "In our previous study, we showed that pioglitazone exerts protective effects on renal ischemia-reperfusion injury (IRI) in mice by abrogating renal cell apoptosis." | 3.79 | Pioglitazone protects against renal ischemia-reperfusion injury by enhancing antioxidant capacity. ( Hu, H; Huang, X; Shi, Z; Wang, G; Xi, X; Zou, C, 2013) |
| " We examined the effects of pioglitazone, a synthetic ligand of PPAR-gamma, against lung ischemia-reperfusion injury in rats." | 3.72 | Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on lung ischemia-reperfusion injury in rats. ( Ito, K; Kato, D; Kitamura, N; Naito, Y; Shimada, J; Takagi, T; Toda, S; Yoshikawa, T, 2004) |
| "In rats subjected to cerebral ischemia, post-ischemic treatment with either dose of pioglitazone alleviated particular motor deficits and sensory impairments on day 2 after MCAO." | 2.77 | Treatment of rats with pioglitazone in the reperfusion phase of focal cerebral ischemia: a preclinical stroke trial. ( Culman, J; Glatz, T; Gohlke, P; Herdegen, T; Nguyen-Ngoc, M; Zhao, Y, 2012) |
| "The treatment of reperfusion injury after ischemic stroke remains unsatisfactory since the blood-brain barrier (BBB) prevents most neuroprotective agents from entering the brain." | 1.91 | Bacteria-Derived Outer-Membrane Vesicles Hitchhike Neutrophils to Enhance Ischemic Stroke Therapy. ( Guo, X; Huang, X; Pan, J; Wang, Z; Xue, J; Zhang, S; Zhou, S, 2023) |
| "Histopathological findings were correlated with the Western blot results and depict a protective effect corresponding to the elevated dosage of Pioglitazone regarding in situ perfusion rat model." | 1.62 | Effect of Pioglitazone on endoplasmic reticulum stress regarding in situ perfusion rat model. ( Balogh, B; Caleb, I; Erlitz, L; Hardi, P; Jancsó, G; Nagy, T; Sétáló, G; Takács, I; Telek, V; Vecsernyés, M, 2021) |
| "Pre-treatment with fenofibrate and pioglitazone in addition to their combination improved neurobehavioral dysfunction, reduced cerebral infarct volume, attenuated inflammatory and apoptotic markers and ameliorated histopathological changes in I/R injured rats." | 1.56 | The impact of single and combined PPAR-α and PPAR-γ activation on the neurological outcomes following cerebral ischemia reperfusion. ( Abdelrehim, AB; Ahmed, AF; Heeba, GH; Shehata, AHF, 2020) |
| "Ischemia reperfusion injury (IRI) during liver-metastasis resection for treatment of colon cancer may increase the risk of further metastasis." | 1.56 | Ischemia reperfusion-induced metastasis is resistant to PPARγ agonist pioglitazone in a murine model of colon cancer. ( Aoki, T; Bouvet, M; Fukuda, Y; Higuchi, T; Hoffman, RM; Inubushi, S; Murakami, M; Nishino, H; Singh, SR; Sugisawa, N; Tashiro, Y; Yamamoto, J, 2020) |
| "Pioglitazone (10mg/kg; po) was administered daily for 2 weeks prior to I/R." | 1.42 | Neuroprotective effects of pioglitazone against transient cerebral ischemic reperfusion injury in diabetic rats: Modulation of antioxidant, anti-inflammatory, and anti-apoptotic biomarkers. ( Ain-Shoka, AA; Attia, AS; El-Sahar, AE; Safar, MM; Zaki, HF, 2015) |
| "Pretreatment with cilostazol or pioglitazone provided significant protection against the I/R-induced renal injury as manifested by the attenuated serum levels of creatinine, blood urea nitrogen and cystatin C." | 1.40 | Cilostazol renoprotective effect: modulation of PPAR-γ, NGAL, KIM-1 and IL-18 underlies its novel effect in a model of ischemia-reperfusion. ( Abdallah, DM; El-Abhar, HS; Ragab, D, 2014) |
| "Pioglitazone pretreatment also suppressed NF-κB activation and altered GFAP overexpression." | 1.39 | Protective effect of pioglitazone on retinal ischemia/reperfusion injury in rats. ( Xiao, YQ; Ye, W; Zhang, XY; Zhang, Y, 2013) |
| "Pioglitazone is a novel class of oral antidiabetic agents currently used to treat type 2 diabetes mellitus." | 1.38 | Protective effects of pioglitazone on renal ischemia-reperfusion injury in mice. ( Hu, H; Huang, X; Shi, Z; Wang, G; Xi, X; Zou, C, 2012) |
| "Treatment with pioglitazone or telmisartan demonstrated a significant improvement in the reperfusion-induced renal injury in comparison with diabetic I/R group, without difference between the two treated groups." | 1.38 | Renoprotective activity of telmisartan versus pioglitazone on ischemia/reperfusion induced renal damage in diabetic rats. ( Tawfik, MK, 2012) |
| "Pioglitazone can suppress the oxidative stress and damage and can stimulate antioxidant capacity in cardiac allografts after transplantation." | 1.37 | Antioxidant properties of pioglitazone limit nicotinamide adenine dinucleotide phosphate hydrogen oxidase and augment superoxide dismutase activity in cardiac allotransplantation. ( Hasegawa, T; Okada, K; Okita, Y; Pinsky, DJ, 2011) |
| "Pioglitazone treatment reduced the infarct size and improved neurological functions." | 1.35 | Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia. ( Culman, J; Gohlke, P; Herdegen, T; Patzer, A; Stöck, I; Zhao, Y, 2008) |
| "Pioglitazone pretreatment also attenuated the oxidative stress and DNA fragmentation after cerebral IR injury." | 1.35 | Protective effects of pioglitazone against global cerebral ischemic-reperfusion injury in gerbils. ( Iyer, S; Kaundal, RK; Kumar, A; Sharma, SS, 2009) |
| "Pioglitazone pretreatment significantly reduced liver enzyme content (ALT, 176." | 1.35 | Pioglitazone attenuates ischemia/reperfusion-induced liver injury in rats. ( Asl, NA; Azar, AN; Estakhri, R; Haghjou, AG; Hajipour, B; Somi, MH; Vatankhah, AM; Zade, MN, 2009) |
| "Pioglitazone treatment significantly inhibited hepatic I/R injury as determined by serological and histological analyses." | 1.34 | Importance of peroxisome proliferator-activated receptor-gamma in hepatic ischemia/reperfusion injury in mice. ( Akahori, T; Enomoto, K; Hamada, K; Kanehiro, H; Kuzumoto, Y; Nakajima, Y; Nakamura, S; Nomi, T; Sho, M; Suzaki, Y, 2007) |
| "Pioglitazone was given to the rats intraperitoneally 2 h before the vascular clamping." | 1.31 | A specific peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats. ( Ichikawa, H; Naito, Y; Takagi, T; Tomatsuri, N; Yoshida, N; Yoshikawa, T, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (38.46) | 29.6817 |
| 2010's | 19 (48.72) | 24.3611 |
| 2020's | 5 (12.82) | 2.80 |
| Authors | Studies |
|---|---|
| Li, L | 1 |
| Pan, G | 1 |
| Fan, R | 1 |
| Li, D | 1 |
| Guo, L | 1 |
| Ma, L | 1 |
| Liang, H | 1 |
| Qiu, J | 1 |
| Pan, J | 1 |
| Wang, Z | 1 |
| Huang, X | 3 |
| Xue, J | 1 |
| Zhang, S | 1 |
| Guo, X | 1 |
| Zhou, S | 1 |
| Shehata, AHF | 1 |
| Ahmed, AF | 1 |
| Abdelrehim, AB | 1 |
| Heeba, GH | 1 |
| Tashiro, Y | 1 |
| Nishino, H | 1 |
| Higuchi, T | 1 |
| Sugisawa, N | 1 |
| Fukuda, Y | 1 |
| Yamamoto, J | 1 |
| Inubushi, S | 1 |
| Aoki, T | 1 |
| Murakami, M | 1 |
| Singh, SR | 1 |
| Bouvet, M | 1 |
| Hoffman, RM | 1 |
| Telek, V | 1 |
| Erlitz, L | 1 |
| Caleb, I | 1 |
| Nagy, T | 1 |
| Vecsernyés, M | 1 |
| Balogh, B | 1 |
| Sétáló, G | 1 |
| Hardi, P | 1 |
| Jancsó, G | 1 |
| Takács, I | 1 |
| Pane, B | 1 |
| Gazzola, V | 1 |
| Spinella, G | 1 |
| Bagnato, P | 1 |
| Grillo, F | 1 |
| Vellone, VG | 1 |
| Palombo, D | 1 |
| Xia, P | 1 |
| Pan, Y | 1 |
| Zhang, F | 1 |
| Wang, N | 1 |
| Wang, E | 1 |
| Guo, Q | 1 |
| Ye, Z | 1 |
| Ali, RM | 1 |
| Al-Shorbagy, MY | 1 |
| Helmy, MW | 1 |
| El-Abhar, HS | 2 |
| Refaie, MMM | 1 |
| El-Hussieny, M | 1 |
| Elshazly, S | 1 |
| Soliman, E | 1 |
| Zou, C | 2 |
| Hu, H | 2 |
| Xi, X | 2 |
| Shi, Z | 2 |
| Wang, G | 2 |
| Zhang, XY | 1 |
| Xiao, YQ | 1 |
| Zhang, Y | 1 |
| Ye, W | 1 |
| Ragab, D | 1 |
| Abdallah, DM | 1 |
| Sakatani, Y | 1 |
| Miyoshi, T | 1 |
| Oe, H | 1 |
| Noda, Y | 1 |
| Ohno, Y | 1 |
| Nakamura, K | 1 |
| Saito, Y | 1 |
| Osawa, K | 1 |
| Morita, H | 1 |
| Kohno, K | 1 |
| Ito, H | 1 |
| Abdel-Rahman, EM | 1 |
| Okusa, MD | 1 |
| El-Sahar, AE | 1 |
| Safar, MM | 1 |
| Zaki, HF | 1 |
| Attia, AS | 1 |
| Ain-Shoka, AA | 1 |
| Macan, M | 1 |
| Vukšić, A | 1 |
| Žunec, S | 1 |
| Konjevoda, P | 1 |
| Lovrić, J | 1 |
| Kelava, M | 1 |
| Štambuk, N | 1 |
| Vrkić, N | 1 |
| Bradamante, V | 1 |
| Singh, AP | 1 |
| Singh, N | 1 |
| Bedi, PM | 1 |
| Patzer, A | 1 |
| Zhao, Y | 2 |
| Stöck, I | 1 |
| Gohlke, P | 2 |
| Herdegen, T | 2 |
| Culman, J | 2 |
| Ji, S | 1 |
| Kronenberg, G | 1 |
| Balkaya, M | 1 |
| Färber, K | 1 |
| Gertz, K | 1 |
| Kettenmann, H | 1 |
| Endres, M | 1 |
| Kaundal, RK | 1 |
| Iyer, S | 1 |
| Kumar, A | 1 |
| Sharma, SS | 1 |
| Rahimian, R | 1 |
| Fakhfouri, G | 1 |
| Rasouli, MR | 1 |
| Nouri, M | 1 |
| Nezami, BG | 2 |
| Paydar, MJ | 1 |
| Asadi-Amoli, F | 1 |
| Dehpour, AR | 2 |
| Somi, MH | 1 |
| Hajipour, B | 1 |
| Asl, NA | 1 |
| Estakhri, R | 1 |
| Azar, AN | 1 |
| Zade, MN | 1 |
| Haghjou, AG | 1 |
| Vatankhah, AM | 1 |
| Hasegawa, T | 1 |
| Okada, K | 1 |
| Okita, Y | 1 |
| Pinsky, DJ | 1 |
| Afraz, S | 1 |
| Kamran, A | 1 |
| Moazzami, K | 1 |
| Tawfik, MK | 1 |
| Reel, B | 1 |
| Guzeloglu, M | 1 |
| Bagriyanik, A | 1 |
| Atmaca, S | 1 |
| Aykut, K | 1 |
| Albayrak, G | 1 |
| Hazan, E | 1 |
| Nguyen-Ngoc, M | 1 |
| Glatz, T | 1 |
| Naito, Y | 4 |
| Takagi, T | 3 |
| Uchiyama, K | 1 |
| Handa, O | 1 |
| Tomatsuri, N | 2 |
| Imamoto, E | 1 |
| Kokura, S | 1 |
| Ichikawa, H | 2 |
| Yoshida, N | 2 |
| Yoshikawa, T | 4 |
| Konturek, PC | 1 |
| Brzozowski, T | 1 |
| Kania, J | 1 |
| Kukharsky, V | 1 |
| Bazela, K | 1 |
| Kwiecien, S | 1 |
| Harsch, I | 1 |
| Konturek, SJ | 1 |
| Hahn, EG | 1 |
| Ito, K | 1 |
| Shimada, J | 1 |
| Kato, D | 1 |
| Toda, S | 1 |
| Kitamura, N | 1 |
| Shimazu, T | 1 |
| Inoue, I | 1 |
| Araki, N | 1 |
| Asano, Y | 1 |
| Sawada, M | 1 |
| Furuya, D | 1 |
| Nagoya, H | 1 |
| Greenberg, JH | 1 |
| Collino, M | 1 |
| Aragno, M | 1 |
| Mastrocola, R | 1 |
| Gallicchio, M | 1 |
| Rosa, AC | 1 |
| Dianzani, C | 1 |
| Danni, O | 1 |
| Thiemermann, C | 1 |
| Fantozzi, R | 1 |
| Ye, Y | 1 |
| Lin, Y | 1 |
| Atar, S | 1 |
| Huang, MH | 1 |
| Perez-Polo, JR | 1 |
| Uretsky, BF | 1 |
| Birnbaum, Y | 1 |
| Akahori, T | 1 |
| Sho, M | 1 |
| Hamada, K | 1 |
| Suzaki, Y | 1 |
| Kuzumoto, Y | 1 |
| Nomi, T | 1 |
| Nakamura, S | 1 |
| Enomoto, K | 1 |
| Kanehiro, H | 1 |
| Nakajima, Y | 1 |
| Matsuhashi, N | 1 |
| Watanabe, K | 1 |
| Kanamori, H | 1 |
| Ohnishi, S | 1 |
| Omata, M | 1 |
2 reviews available for pioglitazone and Reperfusion Injury
| Article | Year |
|---|---|
Effects of aging on renal function and regenerative capacity.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Aging; Animals; Cellular Senescence; Disease Models, A | 2014 |
Thiazolidinediones: a new class of drugs for the therapy of ischemia-reperfusion injury.
Topics: Animals; Anti-Inflammatory Agents; Chromans; Humans; Ligands; Pioglitazone; Receptors, Cytoplasmic a | 2004 |
2 trials available for pioglitazone and Reperfusion Injury
| Article | Year |
|---|---|
Pioglitazone prevents the endothelial dysfunction induced by ischemia and reperfusion in healthy subjects.
Topics: Adult; Blood Flow Velocity; Brachial Artery; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 | 2014 |
Treatment of rats with pioglitazone in the reperfusion phase of focal cerebral ischemia: a preclinical stroke trial.
Topics: Analysis of Variance; Animals; Brain Infarction; Brain Ischemia; Caspase 9; Cerebral Cortex; Cycloox | 2012 |
35 other studies available for pioglitazone and Reperfusion Injury
| Article | Year |
|---|---|
Luteolin alleviates inflammation and autophagy of hippocampus induced by cerebral ischemia/reperfusion by activating PPAR gamma in rats.
Topics: Animals; Autophagy; Brain Ischemia; Hippocampus; Inflammation; Luteolin; Molecular Docking Simulatio | 2022 |
Bacteria-Derived Outer-Membrane Vesicles Hitchhike Neutrophils to Enhance Ischemic Stroke Therapy.
Topics: Bacteria; Extracellular Vesicles; Humans; Ischemic Stroke; Neutrophils; Pioglitazone; Reperfusion In | 2023 |
The impact of single and combined PPAR-α and PPAR-γ activation on the neurological outcomes following cerebral ischemia reperfusion.
Topics: Animals; Apoptosis; Brain; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Drug Therapy | 2020 |
Ischemia reperfusion-induced metastasis is resistant to PPARγ agonist pioglitazone in a murine model of colon cancer.
Topics: Animals; Colonic Neoplasms; Cytokines; Disease Models, Animal; Disease Progression; Inflammation; Li | 2020 |
Effect of Pioglitazone on endoplasmic reticulum stress regarding in situ perfusion rat model.
Topics: Animals; Endoplasmic Reticulum Stress; Male; Perfusion; Pioglitazone; Rats; Rats, Wistar; Reperfusio | 2021 |
Inflammatory Response Modulation through a PPARγ Agonist during Surgically Induced Visceral Ischemia in an Animal Model.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Constriction; Cytoprotection; Disease Models, Animal; Infl | 2018 |
Pioglitazone Confers Neuroprotection Against Ischemia-Induced Pyroptosis due to its Inhibitory Effects on HMGB-1/RAGE and Rac1/ROS Pathway by Activating PPAR-ɤ.
Topics: Animals; Astrocytes; Cells, Cultured; Glucose; HMGB1 Protein; Infarction, Middle Cerebral Artery; Ma | 2018 |
Role of Wnt4/β-catenin, Ang II/TGFβ, ACE2, NF-κB, and IL-18 in attenuating renal ischemia/reperfusion-induced injury in rats treated with Vit D and pioglitazone.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; beta Catenin; Cytoprotection; Disease Mode | 2018 |
Protective effect of pioglitazone on ovarian ischemia reperfusion injury of female rats via modulation of peroxisome proliferator activated receptor gamma and heme-oxygenase 1.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Heme Oxygenase (Decyclizi | 2018 |
PPAR gamma agonist, pioglitazone, rescues liver damage induced by renal ischemia/reperfusion injury.
Topics: Acute Kidney Injury; Animals; Caspase 3; Kidney; Liver; Liver Diseases; Male; Pioglitazone; PPAR gam | 2019 |
Pioglitazone protects against renal ischemia-reperfusion injury by enhancing antioxidant capacity.
Topics: Animals; Antioxidants; Apoptosis; Blood Urea Nitrogen; Creatinine; Kidney; Lipid Peroxidation; Male; | 2013 |
Protective effect of pioglitazone on retinal ischemia/reperfusion injury in rats.
Topics: Animals; bcl-2-Associated X Protein; Blotting, Western; Cell Count; Cell Survival; Disease Models, A | 2013 |
Cilostazol renoprotective effect: modulation of PPAR-γ, NGAL, KIM-1 and IL-18 underlies its novel effect in a model of ischemia-reperfusion.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Animals; Blood Urea Nitrogen; Caspase 1; Cell Adhesion Mo | 2014 |
Neuroprotective effects of pioglitazone against transient cerebral ischemic reperfusion injury in diabetic rats: Modulation of antioxidant, anti-inflammatory, and anti-apoptotic biomarkers.
Topics: Animals; Antioxidants; Apoptosis; Apoptosis Regulatory Proteins; Brain Ischemia; Carotid Artery, Com | 2015 |
Effects of simvastatin on malondialdehyde level and esterase activity in plasma and tissue of normolipidemic rats.
Topics: Animals; Antioxidants; Apoptosis; Apoptosis Regulatory Proteins; Brain Ischemia; Carotid Artery, Com | 2015 |
Pioglitazone ameliorates renal ischemia reperfusion injury through NMDA receptor antagonism in rats.
Topics: Animals; Kidney Diseases; Male; Pioglitazone; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; R | 2016 |
Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia.
Topics: Animals; Anti-Inflammatory Agents; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Ence | 2008 |
Acute neuroprotection by pioglitazone after mild brain ischemia without effect on long-term outcome.
Topics: Adenosine Triphosphate; Animals; Animals, Newborn; Bromodeoxyuridine; Calcium-Binding Proteins; Cell | 2009 |
Protective effects of pioglitazone against global cerebral ischemic-reperfusion injury in gerbils.
Topics: Animals; Brain Ischemia; Disease Models, Animal; DNA Fragmentation; Gerbillinae; Hippocampus; Hyperk | 2009 |
Effect of pioglitazone on sciatic nerve ischemia/reperfusion injury in rats.
Topics: Animals; Behavior, Animal; Edema; Male; Pioglitazone; Rats; Rats, Sprague-Dawley; Reperfusion Injury | 2009 |
Pioglitazone attenuates ischemia/reperfusion-induced liver injury in rats.
Topics: Animals; Anti-Bacterial Agents; Glutathione Peroxidase; Liver; Male; Malondialdehyde; Pioglitazone; | 2009 |
Antioxidant properties of pioglitazone limit nicotinamide adenine dinucleotide phosphate hydrogen oxidase and augment superoxide dismutase activity in cardiac allotransplantation.
Topics: Animals; Graft Survival; Heart Transplantation; Hypoglycemic Agents; Lipid Peroxidation; Male; Mice; | 2011 |
Protective effect of pharmacologic preconditioning with pioglitazone on random-pattern skin flap in rat is mediated by nitric oxide system.
Topics: Animals; Arginine; Dermatologic Surgical Procedures; Enzyme Inhibitors; Graft Survival; Hypoglycemic | 2012 |
Protective effects of pioglitazone on renal ischemia-reperfusion injury in mice.
Topics: Acute Kidney Injury; Animals; Apoptosis; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Hy | 2012 |
Renoprotective activity of telmisartan versus pioglitazone on ischemia/reperfusion induced renal damage in diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Catalase | 2012 |
The effects of PPAR-γ agonist pioglitazone on renal ischemia/reperfusion injury in rats.
Topics: Animals; Antioxidants; Kidney; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Models, | 2013 |
Suppression of intestinal ischemia-reperfusion injury by a specific peroxisome proliferator-activated receptor-gamma ligand, pioglitazone, in rats.
Topics: Animals; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Hypoglycemic Agents; I | 2002 |
A specific peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats.
Topics: Animals; Chemokines; Chemokines, CXC; Chemotactic Factors; Dose-Response Relationship, Drug; Gastric | 2002 |
Pioglitazone, a specific ligand of the peroxisome proliferator-activated receptor gamma reduces gastric mucosal injury induced by ischaemia/ reperfusion in rat.
Topics: Amino Acid Sequence; Animals; Cyclooxygenase 1; Cyclooxygenase 2; Gastric Mucosa; Hypoglycemic Agent | 2003 |
Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on lung ischemia-reperfusion injury in rats.
Topics: Animals; Capillary Permeability; Cytokines; Ligands; Lipid Peroxidation; Lung; Male; Microcirculatio | 2004 |
A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia.
Topics: Animals; Blood-Brain Barrier; Blotting, Western; Brain; Brain Ischemia; Cerebrovascular Circulation; | 2005 |
Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion.
Topics: Animals; Brain Ischemia; Cyclooxygenase 2; Hippocampus; Inflammation; Injections, Intravenous; Lipid | 2006 |
Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug S | 2006 |
Importance of peroxisome proliferator-activated receptor-gamma in hepatic ischemia/reperfusion injury in mice.
Topics: Animals; Apoptosis; Cytokines; Gene Expression Regulation; Hepatocytes; Inflammation; Liver Diseases | 2007 |
PPARgamma agonists for intestinal ischaemia.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; | 2001 |